Tempus AI's 70% Rally Just Stopped at the $73 Midpoint of Its Own Crash — the Line That Decides $80 or a Round-Trip

Tempus AI's 70% Rally Just Stopped at the $73 Midpoint of Its Own Crash — the Line That Decides $80 or a Round-Trip

Tempus AI closed the week up 39.5%, and Friday's pop parked the stock within cents of the statistical middle of its $104-to-$41 bear leg. A daily close above $72.96 keeps the squeeze aimed at $80. A close below $65.25 turns this week's buyers into the next resistance.

Tempus AI closed Friday at $72.69 — up 9.1% on the day, 39.5% over the previous five sessions, and roughly 70% in a month. When a stock moves that far that fast, the question stops being "is anything happening?" and becomes "is the move finished?"

Look where the move stopped. Friday's high was $72.96. The midpoint of TEM's entire bear leg — the fall from its $104.32 high to its $40.77 low — sits at $72.55. The stock spent Friday climbing into a zone where traders have been trapped since late last year, and closed a hair above the statistical center of its own crash. That is not a round number invented off the quote. It is a level with arithmetic memory, and it now organizes everyone's incentives.

What produced the run

Three weeks ago TEM was a low-$40s stock near its 52-week low. On July 20 the company announced an all-stock deal to buy Personalis for roughly $1.5 billion — and the market's first answer was a sell: shares fell 8.9% that day to about $47.78. On the surface this was dilution, paying up for a small player in molecular residual disease (MRD) testing. The tape said no.

A week later Q2 earnings changed the setup. Revenue came in at $382.5 million, management raised full-year guidance to roughly $1.6 billion — about 25% growth — and the company printed its first positive GAAP net income. Then the detonator: on August 19, Merck and Moderna reported positive Phase 3 results for INTerpath-001, the first successful late-stage trial of a personalized mRNA cancer vaccine — and the sequencing engine behind that program is built by Personalis' NeXT Personal, the very company TEM just agreed to buy. TEM closed the day up roughly 24%. Friday added another 9% on 15.97 million shares and $1.13 billion of turnover — about three times the 5.2-million-share daily norm. Participation is not in question.

One number deserves a second look before reading the chart as pure momentum. The "first profit" was a net income print of $5.6 million — flattered by a $97.4 million non-cash fair-value gain on Tempus' existing Personalis stake; the underlying operating line is closer to break-even. The fundamentals that actually carry the story — raised guidance, MRD volume up 38% quarter over quarter, a Medicare-priced test cycle starting in 2027 — are real. But the profitability headline is softer than it reads, which matters when a stock is priced for a re-rating.

Who is under pressure

This is where the technical contest actually lives. TEM was 24.3% of the float sold short as of July 31 — 33.2 million shares — and short interest was still climbing into that report. A heavily shorted stock that rallies 70% in a month forces covering on every up day; that is the fuel under this move. But fuel is not ignition. Ignition is the price that frees the shorts to add again.

The same $70-73 zone is where TEM lived last December and January — the stock slumped to the mid-$60s before the next leg down. Everyone who bought that dip is now back to break-even, and break-even supply is the most reliable ceiling there is. Friday's rally ran into a genuine collision: squeeze demand from the short side meeting supply from trapped long-term holders, at the exact midpoint of the range that defines the whole chart. The outcome is not decided — which is exactly why this level, rather than the momentum, is the story.

The line that matters

Everything now runs through $73. That is three independent facts stacking on one price: Friday's high of $72.96, the $72.55 midpoint, and the round number itself. Above it, the squeeze's first destination is about $80 — the 61.8% retracement of the bear leg, roughly 10% from Friday's close — with the late-2025 supply band around $88-94 beyond it.

Below it, the map flips. Friday's low was $65.25 against a prior close of $66.65. If a daily close lands below $65.25, the reclaim thesis is broken, this breakout's late buyers become the overhead supply, and the next real shelf is the round $60 level, then the low-$50s base where the run began.

What most people are missing

Friday's internals deserve one honest read: the session opened below Thursday's close, tagged $65.25, and closed near the high — a reclaim, not a blowoff. Order-flow data for the day shows block and large orders as net buyers while the retail bucket was a net seller of roughly $10 million. One day of flow is a clue, not a conclusion — but it is the opposite of a crowd-buying-a-top pattern, and it is worth watching whether it repeats.

Now the honest math on entry. TEM is a roughly 6% ATR stock — the 14-day average true range is about $4.40 — and RSI sits at 75. Five-to-ten-percent daily swings are the normal course here, in both directions. From Friday's $72.69, the distance to $80 is about +10%; the distance to the $65.25 invalidation is about -10%. That symmetry is the tell: the asymmetric, low-risk entry died weeks ago at the low-$40s base. Anyone buying here is paying the going rate for a coin flip with an expensive downside tail. The disciplined play is not to chase — it is to let the stock announce which side of $73 it closes on.

Scenario	Trigger	Path	Invalidation	Horizon
Squeeze resumes	Daily close above $72.96	Toward ~$80 (61.8% retrace), then the $88-94 supply band	Close back below $65.25	Days to ~2 weeks
Trapped-buyer reversal	Daily close below $65.25	Toward round $60, then the low-$50s launch base	Reclaim of $73	Days to weeks

Verdict

Hold a daily close above $72.96 and the squeeze keeps $80 in play, with a real chance that covering extends it. Lose $65.25 on a close and this becomes a round-trip map with this week's buyers supplying the descent. Between those two prices, TEM is a stretched, heavily shorted stock spinning around a big number on six-percent daily swings — and the only information that matters is which close comes first.